submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on January 8, 2025, Scottsdale Research Institute, 12815 North Cave Creek Road, Phoenix, Arizona 85022, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana Extract Marihuana Tetrahydrocannabinols	7350 7360 7370	 

The company plans to bulk manufacture the listed controlled substances to support clinical trials and distribution to their customers for research purposes. No other activities for these drug codes are authorized for this registration.

#### Matthew Strait,

Deputy Assistant Administrator. [FR Doc. 2025–02733 Filed 2–14–25; 8:45 am] BILLING CODE P

#### **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

[Docket No. DEA-1499]

Bulk Manufacturer of Controlled Substances Application: Scottsdale Research Institute

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

SUMMARY: Scottsdale Research Institute has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 21, 2025. Such persons may also file a written request for a hearing on the application on or before April 21, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. SUPPLEMENTARY INFORMATION: In

accordance with 21 CFR 1301.33(a), this is notice that on January 8, 2025, Scottsdale Research Institute, 12815 North Cave Creek Road, Phoenix, Arizona 85022, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Ibogaine	7260 7405	1

The company plans to bulk manufacture the listed controlled substances for internal research and analytical development purposes. No other activities for these drug codes are authorized for this registration.

# Matthew Strait,

Deputy Assistant Administrator. [FR Doc. 2025–02739 Filed 2–14–25; 8:45 am] BILLING CODE P

# **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

[Docket No. DEA-1493]

Importer of Controlled Substances Application: Mylan Pharmaceuticals, Inc.

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Mylan Pharmaceuticals, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before March 20, 2025. Such persons may also file a written request for a hearing on the application on or before March 20, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on December 5, 2024, Mylan Pharmaceuticals Inc., 2898 Manufacturers Road, Greensboro, North Carolina 27406–4600, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Remifentanil	9739	II

The company plans to import the listed controlled substance in finished dosage form for commercial distribution to its customers. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug

Administration-approved or non-approved finished dosage forms for commercial sale.

## Matthew Strait,

Deputy Assistant Administrator. [FR Doc. 2025–02732 Filed 2–14–25; 8:45 am] BILLING CODE 4410–09–P

### **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

[Docket No. DEA-1498]

Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Patheon API Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 21, 2025. Such persons may also file a written request for a hearing on the application on or before April 21, 2025.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

# SUPPLEMENTARY INFORMATION: In

accordance with 21 CFR 1301.33(a), this is notice that on January 16, 2025, Patheon API Inc., 6173 East Old Marion Highway, Florence, South Carolina 29506 applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Psilocybin	7437 7438	I I

The company plans to import the listed controlled substances as reference standards for research and development as part of API Manufacturing. No other activities for these drug codes are authorized for this registration.

#### Matthew Strait,

Deputy Assistant Administrator. [FR Doc. 2025–02738 Filed 2–14–25; 8:45 am]

#### **DEPARTMENT OF JUSTICE**

# **Drug Enforcement Administration**

[Docket No. DEA-1496]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceuticals, Inc.

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Janssen Pharmaceuticals, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 21, 2025. Such persons may also file a written request for a hearing on the application on or before April 21, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this

is notice that on December 4, 2024, Janssen Pharmaceuticals, Inc., 1440 Olympic Drive, Buildings 1–5 and 7–14, Athens, Georgia 30601–1645, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Methylphenidate	1724	
Hydromorphone	9150	
Tapentadol	9780	

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates for sale to its customers. No other activities for these drug codes are authorized for this registration.

#### Matthew Strait,

Deputy Assistant Administrator. [FR Doc. 2025–02740 Filed 2–14–25; 8:45 am] BILLING CODE P

#### **DEPARTMENT OF JUSTICE**

# Drug Enforcement Administration [Docket No. DEA-1492]

Bulk Manufacturer of Controlled

**AGENCY:** Drug Enforcement Administration, Justice. **ACTION:** Notice of application.

**SUMMARY:** Purisys, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

**Substances Application: Purisys, LLC** 

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before April 21, 2025. Such persons may also file a written request for a hearing on the application on or before April 21, 2025.

Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public